Isavuconazole

Aspergillosis

Astellas Pharma IncSmall moleculePhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Aspergillosis cohort.

Asset / Sponsor	Phase	Rating
Itraconazole Rennes University Hospital	Phase 2	B
Voriconazole Rennes University Hospital	Phase 2	B
Posaconazole Bambino Gesù Hospital and Research Institute	Phase 2/3	B
OPELCONAZOLE(INN) Pulmocide Ltd	Phase 2	CCC
Fluconazole Bochud Pierre-Yves	N/A	D

Same molecule, other indications

Isavuconazole is also rated in:

systemic mycosisDormant

BB

Indicative ·

64 / 100

acute myeloid leukemiaDormant

B

Indicative ·

62 / 100

primary central nervous system lymphomaDormant

B

Indicative ·

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.